EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, Martine Gehin, Priska Kaufmann

Drugs in R&D · 2024

DOI: 10.1007/s40268-024-00456-8 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Drugs in R&D, 2024. Verfasst von Isabelle Zenklusen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland. Hauptthemen laut MEDLINE: Drug Interactions, Midazolam, Warfarin, Imidazoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Idorsia Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Daridorexant, a dual orexin receptor antagonist was recently approved for the treatment of insomnia at doses up to 50 mg once per night. This study investigated the effect of single-dose and multiple-dose daridorexant 50 mg at steady state on the pharmacokinetics (PK) of the cytochrome P450 (CYP) 3A4-sensitive substrate midazolam, and the effect of single-dose daridorexant 50 mg on the PK and pharmacodynamics (PD) of the CYP2C9-sensitive substrate warfarin. METHODS: In this prospective, single-center, open-label, fixed-sequence, phase I, drug-drug interaction study, 18 healthy male subjects sequentially received Treatment A, B, and C in three periods. Treatment A consisted of a single oral concomitant administration of midazolam 2 mg and warfarin 25 mg on day 1 of the first period. Treatment B consisted of one oral administration of daridorexant 50 mg followed 1 h later by a single oral dose of midazolam 2 mg concomitantly with a single oral dose of warfarin 25 mg on day 1 and a once-daily oral administration of daridorexant 50 mg for 6 days of the second period. Treatment C consisted of a single oral administration of daridorexant 50 mg at steady state followed 1 h later by a single oral administration of midazolam 2 mg on day 1 of the third period. Blood samples were assessed for midazolam and S-warfarin PK, and PD (international normalized ratio and factor VII). Noncompartmental PK parameters and PD variables were evaluated with geometric mean ratios and 90% confidence intervals of Treatment B/A versus C/A for midazolam, and treatment B/A for warfarin. Safety and tolerability of each treatment were also assessed. RESULTS: Midazolam maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from 0 to 24 h (AUC0-24) were 1.13- and 1.42-fold higher, respectively, after single-dose administration of daridorexant 50 mg compared to administration of midazolam alone, while Cmax and AUC0-24 were 1.12- and 1.35-fold higher, respectively, after administration of daridorexant 50 mg once daily at steady state. Terminal half-life and time to maximum plasma concentration were comparable between treatments. Daridorexant had no influence on the PK and PD of warfarin. All treatments were safe and well tolerated. CONCLUSIONS: Daridorexant at 50 mg is classified as a weak CYP3A4 inhibitor after single- and multiple-dose administration once daily at steady state. Daridorexant 50 mg did not induce CYP3A4 activity or inhibit CYP2C9 activity. CLINICAL TRIAL REGISTRATION: This trial (NCT05480488) was registered on 29 July, 2022.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug InteractionsMidazolamWarfarinImidazolesPyrrolidinesHumansMaleAdultYoung AdultHealthy VolunteersTriazolesProspective StudiesOrexin Receptor AntagonistsArea Under Curve

Substanzen

MidazolamWarfarindaridorexantTriazolesOrexin Receptor AntagonistsImidazolesPyrrolidines

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
  • Nuvisan GmbH, Neu-Ulm, Germany.
  • Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland. martine.gehin-beurne@idorsia.com.

Förderung

  • Idorsia Pharmaceuticals

Zitieren

APA

Zenklusen, I., Dingemanse, J., Reh, C., Gehin, M., & Kaufmann, P. (2024). Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs in R&D. https://doi.org/10.1007/s40268-024-00456-8

Vancouver

Zenklusen I, Dingemanse J, Reh C, Gehin M, Kaufmann P. Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs in R&D. 2024. doi:10.1007/s40268-024-00456-8

BibTeX
@article{Zenklusen2024,
  author = {Zenklusen, Isabelle and Dingemanse, Jasper and Reh, Christian and Gehin, Martine and Kaufmann, Priska},
  title = {Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects},
  journal = {Drugs in R&D},
  year = {2024},
  doi = {10.1007/s40268-024-00456-8}
}
Kostenlos starten →